Fetal Physiologically Based Pharmacokinetic Models: Systems Information on the Growth and Composition of Fetal Organs
- PMID: 29987449
- DOI: 10.1007/s40262-018-0685-y
Fetal Physiologically Based Pharmacokinetic Models: Systems Information on the Growth and Composition of Fetal Organs
Abstract
Background: The growth of fetal organs is a dynamic process involving considerable changes in the anatomical and physiological parameters that can alter fetal exposure to xenobiotics in utero. Physiologically based pharmacokinetic models can be used to predict the fetal exposure as time-varying parameters can easily be incorporated.
Objective: The objective of this study was to collate, analyse and integrate the available time-varying parameters needed for the physiologically based pharmacokinetic modelling of xenobiotic kinetics in a fetal population.
Methods: We performed a comprehensive literature search on the physiological development of fetal organs. Data were carefully assessed, integrated and a meta-analysis was performed to establish growth trends with fetal age and weight. Algorithms and models were generated to describe the growth of these parameter values as functions of age and/or weight.
Results: Fetal physiologically based pharmacokinetic parameters, including the size of the heart, liver, brain, kidneys, lungs, spleen, muscles, pancreas, skin, bones, adrenal and thyroid glands, thymus, gut and gonads were quantified as a function of fetal age and weight. Variability around the means of these parameters at different fetal ages was also reported. The growth of the investigated parameters was not consistent (with respect to direction and monotonicity).
Conclusion: Despite the limitations identified in the availability of some values, the data presented in this article provide a unique resource for age-dependent organ size and composition parameters needed for fetal physiologically based pharmacokinetic modelling. This will facilitate the application of physiologically based pharmacokinetic models during drug development and in the risk assessment of environmental chemicals and following maternally administered drugs or unintended exposure to environmental toxicants in this population.
Similar articles
-
Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Blood Components and Binding Proteins.Clin Pharmacokinet. 2020 May;59(5):629-642. doi: 10.1007/s40262-019-00836-3. Clin Pharmacokinet. 2020. PMID: 31696406 Review.
-
Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Cardiac Output and Its Distribution to Different Organs during Development.Clin Pharmacokinet. 2021 Jun;60(6):741-757. doi: 10.1007/s40262-020-00973-0. Epub 2021 Jan 24. Clin Pharmacokinet. 2021. PMID: 33486719 Review.
-
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.Clin Pharmacokinet. 2012 Jun 1;51(6):365-96. doi: 10.2165/11597440-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22515555
-
Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition.Clin Pharmacokinet. 2018 Sep;57(9):1149-1171. doi: 10.1007/s40262-017-0618-1. Clin Pharmacokinet. 2018. PMID: 29264787
-
A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building.Clin Pharmacokinet. 2020 Apr;59(4):485-500. doi: 10.1007/s40262-019-00825-6. Clin Pharmacokinet. 2020. PMID: 31583613
Cited by
-
Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities.Pharmaceutics. 2023 Nov 3;15(11):2579. doi: 10.3390/pharmaceutics15112579. Pharmaceutics. 2023. PMID: 38004559 Free PMC article. Review.
-
Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime.Clin Pharmacokinet. 2024 Jan;63(1):69-78. doi: 10.1007/s40262-023-01323-6. Epub 2023 Nov 14. Clin Pharmacokinet. 2024. PMID: 37962827
-
Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure.Front Pharmacol. 2023 Mar 23;14:1111601. doi: 10.3389/fphar.2023.1111601. eCollection 2023. Front Pharmacol. 2023. PMID: 37033628 Free PMC article. Review.
-
The Analysis of Pethidine Pharmacokinetics in Newborn Saliva, Plasma, and Brain Extracellular Fluid After Prenatal Intrauterine Exposure from Pregnant Mothers Receiving Intramuscular Dose Using PBPK Modeling.Eur J Drug Metab Pharmacokinet. 2023 May;48(3):281-300. doi: 10.1007/s13318-023-00823-x. Epub 2023 Apr 5. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37017867
-
Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.J Clin Pharmacol. 2022 Sep;62 Suppl 1(Suppl 1):S94-S114. doi: 10.1002/jcph.2117. J Clin Pharmacol. 2022. PMID: 36106781 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
